Effect of Troglitazone on Urinary Excretion of 6β‐Hydroxycortisol

Abstract

Coadministration of troglitazone reduces the plasma concentrations of terfenadine and ethinyl estradiol, Because these drugs are metabolized at least in part by cytochrome P450 3A (CYP3A), it is possible that troglitazone induces CYP3A activity, thereby reducing plasma concentrations of these agents. Known inducers of CYP3A, such as rifampin, phenytoin, carbamazepine, and phenobarbital, increase the urinary excretion of 6β‐hydroxycortisol and the ratio of 6β‐hydroxycortisol to cortisol. This evaluation examined the effect of troglitazone on urinary excretion of 6β‐hydroxycortisol and the ratio of 6β‐hydroxycortisol to cortisol as a marker for CYP3A induction. Urine samples were collected from 11 subjects who completed a study evaluating the effect of multiple‐dose administration of troglitazone 400 mg once daily (days 11‐20) on the steadystate pharmacokinetics of digoxin (0.25 mg daily on days 1‐20). A single urine sample was collected at baseline on day 1, and 24‐hour urine samples were collected on days 10 and 20. Mean ± standard deviation 24‐hour excretion rate of cortisol was unchanged, whereas that of 6β‐hydroxycortisol increased during troglitazone administration. The ratio of 24‐hour urinary 6β‐hydroxy‐cortisol to cortisol excretion increased from 7.4 ± 2.7 on day 10 to 16.1 ± 6.2 on day 20. The ratio observed on day 10 was similar to that obtained at baseline. These results are consistent with the hypothesis that troglitazone induces CYP3A activity.